Navigation Links
FierceBiotech Names Obesity Company Gelesis to 'Fierce 15' List of Top Emerging Biotech Companies
Date:9/15/2010

BOSTON, Sept. 15 /PRNewswire/ -- Gelesis, a Boston-based obesity company, announced today that it has been named to the FierceBiotech "Fierce 15" list, designating it as one of the top emerging biotech companies of 2010. The editors evaluated hundreds of privately-held firms based on company vision, revenue potential, quality of deals, strength of technology, partnerships, and competitive market position. Gelesis was determined to be one of the "fiercest" with its novel approach to tackling obesity.

(Logo: http://photos.prnewswire.com/prnh/20080103/NETH025LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20080103/NETH025LOGO)

John Carroll, FierceBiotech's Editor said "This is the first year FierceBiotech readers got a chance to directly nominate a company for the Fierce 15, and some of our most influential subscribers picked Gelesis as one of this year's most promising biotech companies in the industry."

"Gelesis has one of the most novel approaches to the complex challenge of obesity drug discovery that I have seen, both while running worldwide basic research at Merck, and subsequently in the biotech world,"  said Dr. Ben Shapiro, former Executive Vice President of Worldwide Basic and External Research at Merck and a Senior Partner at PureTech Ventures.

Obesity is the largest healthcare-related opportunity in the world, with close to two billion individuals being either overweight or obese according to the World Health Organization. No one has been successful at developing a safe and effective treatment for obesity despite the multi-billion dollar potential for such a product.  

Pharmaceutical attempts have been limited by modest efficacy and challenging safety profiles. Surgical intervention to reduce stomach volume mechanically is effective but the use of this invasive approach is limited to morbidly obese patients. Gelesis has taken an innovative biotech approach to the surgical volume reduction mechanism. The product concept involves the decrease of functional stomach and GI tract volume, with a patient swallowing capsules containing individual particles that swell to 100X their original size in the stomach environment. Delivered in a capsule, Gelesis technology was developed using safe food-grade components and was designed to work mechanically via several physiological mechanisms in the GI tract that induce satiation when one eats a full meal.  A video and animation of the Gelesis technology is available at www.gelesis.com/content/technology.

"Unlike other approaches, Gelesis' technology leverages the body's own physiological mechanisms to increase satiety and decrease hunger," said Yishai Zohar, Co-Founder and Chief Executive Officer of Gelesis. "Creating a technology that is completely non-invasive, uses safe food-grade components, and works through validated GI-localized mechanisms, was a breakthrough that took many years of research."

The Fierce 15 celebrates the spirit of being "fierce" – championing innovation and creativity, even in the face of intense competition. FierceBiotech is the biotech industry's leading daily monitor - an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval and regulation, biotech company deals and more. More than 75,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day's top stories. A complete list of "Fierce 15" companies is available online at www.fiercebiotech.com.

Gelesis, Inc. is a Boston-based obesity company with two programs in clinical development. Gelesis was co-founded by PureTech Ventures and a scientific advisory board of renowned obesity experts and polymer scientists that includes: James Hill MD, Professor of Medicine & Pediatrics at the University of Colorado, and Past President of The Obesity Society (TOS); Lee M. Kaplan, MD, PhD, Director of Massachusetts General Hospital Weight Center and a leading researcher in gastric bypass surgery; Caroline Apovian, MD, Director of the Center for Nutrition and Weight Management at Boston Medical Center and leading obesity clinician; Allan Geliebter, PhD, Senior Attending Psychologist, St. Luke's-Roosevelt Hospital, pioneer of the gastric balloon; Luigi Ambrosio PhD, Head of the Institute for Composite & Biomaterials at the University of Naples; and Stephen Woods, PhD, Professor of Psychiatry and Director of the Obesity Research Center at the University of Cincinnati who discovered fundamental mechanisms of satiation.


'/>"/>
SOURCE Gelesis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amira Pharmaceuticals Named One of Most Promising Biotech Companies by FierceBiotechs Annual Fierce 15
2. FierceBiotech Designates Alder Biopharmaceuticals One of Top Private Biotechs, Member of the 2010 Fierce 15
3. AAIPharma Services Corp. Names Patrick Walsh Chief Executive Officer
4. INC. 5000 Names ClinixMIS for Third Time
5. SL Industries Names Louis J. Belardi Chief Financial Officer
6. BayCare Health System Names Tim Thompson Chief Information Officer
7. Watson Names Sigurdur Oli Olafsson Executive Vice President, Global Generics
8. K-V Pharmaceutical Names Thomas McHugh Chief Financial Officer
9. Ikaria® Names New Chief Financial Officer
10. Codexis Names Peter Strumph SVP, Commercial Operations
11. Gentris Corporation Names New Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... 4, 2016 Global Insulin ... profiling 09 key companies and supported with 272 ... in-depth study on the current state of the ... the industry including definitions, classifications, applications and industry ... provided for the international market including development history, ...
(Date:5/3/2016)... 3, 2016 ACME Markets, ... and Delaware County Councilman Dave White ... in all ACME pharmacies across ... Control and Prevention (CDC), naloxone has saved 26,463 lives nationwide over ... Delaware County were authorized to administer naloxone ...
(Date:5/3/2016)... May 3, 2016 Pharmaceutical giant ... million to a woman who says its talc-based powder ... Gloria Ristesund $5 million in compensatory damages ... (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , This ... the company. In February, the same court awarded $72 ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... May 04, 2016 , ... Cirius, a provider of cloud-based ... Secure Messaging platform, which includes secure, private messaging, large file sharing, secure e-signatures, ... of patents around innovative features for securing, tracking, and controlling messages for organizations ...
(Date:5/4/2016)... ... May 04, 2016 , ... Somnoware Healthcare ... today announced it has secured $9 million in Series A funding led by ... investment will be used by Somnoware to further fulfill its mission to connect, ...
(Date:5/4/2016)... Palm City, Florida (PRWEB) , ... May 04, ... ... providers of cold therapy products, announced today the introduction of the innovative newly ... for post operative hip replacement patients. The plush design enhances comfort and enables ...
(Date:5/4/2016)... ... 04, 2016 , ... a2z, Inc. is pleased to announce ... for Enterostomal Therapy (CAET) will be utilizing powerful and innovative technology solutions to ... exhibitors for the 2016 WOCN Society & CAET Joint Conference—which is the largest ...
(Date:5/4/2016)... ... May 04, 2016 , ... Washington Wellness Center today ... central New Jersey residents. What started out as an idea to provide a ... integrated approach to healthcare. , Developed by Dr. David Swanekamp, Chiropractic Physician , ...
Breaking Medicine News(10 mins):